NYSE : LLY

Eli Lilly and Company

$1196.04 USD

$10.17 (0.86%)

Volume
1.59M
Average Volume
3.19M
Market Capitalization
$1.13T
P/E Ratio
42.41
Dividend Yield
0.54%
Price Target
$1300.00
Year High
$1249.45
Year Low
$623.78
Day High
—
Day Low
—
Payout Ratio
$0.22
Current Ratio
$1.50
Company Overview

NYSE

David A. Ricks

Drug Manufacturers - General

Healthcare

LLY

50000

US

USD

https://www.lilly.com

317 276 2000

532457108

0000059478

Liquidity Metrics

1.39

1.50

1.10

0.14

0.22

Sales & Valuation

$65.18B

15.59

34.29

82.94

15.18

Profitability

$22.95

$20.64B

34.98%

43.08%

101.30%

21.68%

P/E Metrics

42.41

0.33

0.33

Analyst Price Target & Rating

$1300.00

$1500.00

$1135.00

Neutral

3/5

45 Analysts

-8.00%

Financial Health Scores

9.88

6/9

$18.2B

$116.58B

$85.38B

$31.86B

Key Metrics (TTM)

$1.16T

16.12

34.80

1.50

101.30%

32.06%

2.36%

1.21%

$148.91

398 days

Company Executives
Name Title
Lucas E. Montarce Executive Vice President & Chief Financial Officer
Anat Hakim Executive Vice President, General Counsel & Secretary
Ilya Yuffa Executive VP and President of Lilly USA & Global Customer Capabilities
David A. Ricks Chairman & CEO
Diogo Rau Executive VP and Chief Information & Digital Officer
Eric Dozier Executive Vice President & Chief People Officer
Michael Czapar Director of Investor Relations
Daniel Skovronsky Chief Scientific & Product Officer and President of Lilly Research Laboratories
Donald A. Zakrowski Senior Vice President of Finance & Chief Accounting Officer
Jacob S. Van Naarden Executive VP, President of Lilly Oncology & Head of Corporate Business Development
Poll Results

No votes yet today — be the first to share your view!

About Eli Lilly and Company (NYSE:LLY) Stock

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metasta ... tic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Eli Lilly, Dell Among Stocks To Watch As Market Leadership Shifts

2026-07-25 08:00:28

As AI-related stocks weaken, investors are rotating into other sectors, such as energy and health care.

This Catalyst Makes Eli Lilly a Top Growth Stock in 2026

2026-07-24 13:30:36

Eli Lilly (NYSE:LLY | LLY Price Prediction) has accelerated despite its $1 trillion scale.

LLY's Retatrutide Nears 2027 Filing With Two More Phase III Wins

2026-07-24 11:16:23

Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.

As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize

2026-07-24 09:09:00

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.

Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads

2026-07-24 05:48:00

Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.

Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads

2026-07-24 04:41:44

Novo Nordisk said on Friday it is seeking a preliminary U.S. ​court injunction to immediately block obesity ‌and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry ​between the two groups.

2 Top Growth Stocks to Buy Right Now Without Any Hesitation

2026-07-24 00:30:00

There are plenty of reasons to love these companies.

Lilly's Next-Generation Obesity Shot Clears Another Hurdle

2026-07-23 19:25:34

Eli Lilly & Co.'s next-generation weight-loss shot retatrutide didn't increase overall heart risk in a new study, helping dispel concerns over its potential. The company plans to file for US Food and Drug Administration approval early next year, later than investors hoped, due to the complexity of the approval pathway.

Frequently Asked Questions

What is the current Eli Lilly and Company (LLY) stock price?

Eli Lilly and Company(NYSE:LLY) stock price is $1196.04 in the last trading session. During the trading session, LLY stock reached the peak price of $1249.45 while $623.78 was the lowest point it dropped to. The percentage change in LLY stock occurred in the recent session was 0.86% while the dollar amount for the price change in LLY stock was $10.17.

LLY's industry and sector of operation?

The NYSE listed LLY is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of LLY?

Lucas E. Montarce | Executive Vice President & Chief Financial Officer
Anat Hakim | Executive Vice President, General Counsel & Secretary
Ilya Yuffa | Executive VP and President of Lilly USA & Global Customer Capabilities
David A. Ricks | Chairman & CEO
Diogo Rau | Executive VP and Chief Information & Digital Officer

How many employees does LLY have?

Number of LLY employees currently stands at 50000. LLY operates from Lilly Corporate Center, Indianapolis, IN 46285, US.

Link for LLY official website?

Official Website of LLY is: https://www.lilly.com

How do I contact LLY?

LLY could be contacted at phone #317 276 2000 and can also be accessed through its website. LLY operates from Lilly Corporate Center, Indianapolis, IN 46285, US.

How many shares of LLY are traded daily?

The average number of LLY shares traded daily for last 3 months was 3.19M.

What is the market cap of LLY currently?

The market value of LLY currently stands at $1.13T with its latest stock price at $1196.04